Neurogenic Orthostatic Hypotension in MSA: Droxidopa or Midodrine
A single patient with MSA and disabling orthostatic hypotension, choosing between two comparably effective pressor agents whose real difference shows up only after the patient stands back up — or lies back down.
E.M., a 71-year-old woman, still teaches piano twice a week from the bench in her living room — sitting down, she says, is the only part of the day her body still cooperates with. Fourteen months ago a movement-disorder specialist confirmed multiple system atrophy, parkinsonian type, after two years of progressive rigidity, urinary urgency, and a blood pressure that had started dropping hard enough on standing to end two lessons early. She wears compression stockings and rises from bed in stages, but over the past six weeks the near-syncope has started happening even with those precautions, twice with a witnessed loss of consciousness lasting several seconds.
Neurogenic orthostatic hypotension in MSA reflects a preganglionic autonomic lesion — the peripheral sympathetic neurons that would normally release norepinephrine at the vessel wall are largely intact, but the central signal telling them to fire on standing is not. That distinction is what makes droxidopa and midodrine comparably reasonable rather than one obviously correct: droxidopa is itself converted to norepinephrine by the same decarboxylase enzyme that turns levodopa into dopamine, working regardless of what the central signal is doing, while midodrine bypasses norepinephrine release entirely and stimulates the vessel wall's alpha-1 receptor directly. The trial evidence needs reading with her diagnosis in hand. Droxidopa's most-cited pivotal study, NOH306, enrolled patients with Parkinson's disease — not MSA — and its first 51 patients missed the original primary endpoint outright, after which the primary was changed to OHSA item 1 at week 1, where droxidopa did separate from placebo; by week 8 the difference was only a trend. She is MSA-P, so the population that actually included her is the earlier NOH301/302 program, which pooled primary autonomic failure diagnoses together. Midodrine's own older placebo-controlled data (Low et al., 1997) showed a comparable rise in standing systolic pressure. Neither drug separates cleanly from the other on efficacy — nor could either afford to ignore what today's home blood-pressure log actually shows.
That log, the reason she came in early, shows two mornings this week with a supine blood pressure over 170/95, taken before she'd gotten out of bed. She's not just orthostatic; she's already flirting with a supine-hypertension pattern that either drug, dosed carelessly, will make worse.
Clinic visit, choosing a first-line pressor
Her actual complaint is that lessons keep ending because she's about to pass out — droxidopa's pivotal program measured exactly that symptom on the OHSA item-1 dizziness/lightheadedness scale and showed real improvement over placebo. I'll concede the population caveat before you raise it: NOH306 was a Parkinson's disease trial, and she has MSA — the studies that actually enrolled MSA patients are the earlier NOH301 and NOH302, which pooled autonomic failure diagnoses. Midodrine's evidence is real too, but built around raising standing systolic pressure as the outcome, not around how dizzy a patient feels doing it. I'd still start with the drug whose endpoint was designed around her problem.
You're right that NOH306's endpoint maps onto her complaint more directly — I'm not contesting the trial design. But two mornings this week she was over 170 systolic lying flat before either of us had added a pressor, and both of these drugs work by pushing pressure up, not down. Midodrine clears in a few hours; the last dose of the day can sit comfortably before dinner and be essentially gone by the time she's supine overnight. Droxidopa's labeled schedule puts a dose in the late afternoon that runs closer into her sleeping hours — exactly the window her own log says is already a problem.
A trial measuring the right symptom doesn't tell us which drug is safer for a patient whose overnight pressure was already elevated before we started — that population wasn't screened for it. And I'd note the endpoint you're citing is the one the trial switched to after the first cohort missed the original: real, but a week-1 result whose week-8 separation was a trend, in a diagnosis that wasn't hers.
Neither of you is wrong about your own drug's strength, and neither trial population looked like her — pre-existing overnight hypertension wasn't something either enrollment criteria screened heavily for. So this isn't really droxidopa-versus-midodrine as a general question; it's how to run either one safely in a patient who's already there. Start midodrine, dosed at 6 AM, 10 AM, and 2 PM only — never within four hours of lying down, which functionally solves the cardiology timing concern regardless of which drug we'd picked — and raise the head of her bed six to nine inches tonight, before either of you gets your prescription filled. If her daytime symptoms don't improve enough on midodrine alone, droxidopa becomes the second-line switch, not a same-day alternative we're choosing between blind.
Agreed: midodrine 10mg at 6 AM, 10 AM, and 2 PM, head-of-bed elevation started tonight, droxidopa held as the explicit second-line option if daytime symptoms don't adequately improve.
Not agreed: how long to wait before calling midodrine insufficient and switching — the autonomic neurologist wants two weeks given how disruptive her current symptoms already are; the cardiologist wants a full month to let the retimed dosing and bed elevation actually settle her overnight pressure pattern before adding a new variable. They left it at “reassess in two weeks, decide then,” rather than pre-committing to either interval today.